Hepatorenal Effects of Curcumin and Piperine in Lipopolysaccharide-Induced Systemic Inflammation in Wistar Rats: A Review

AKEREDOLU F F[1], EKUNDINA V O[2], AGBOMHERE H.M[3]
College of Medicine and Health Science, Department of Medical Laboratory Science, Afe Babalola University Ado-Ekiti, Ekiti State, Nigeria and Brain will Medical Laboratory Limited.

Abstract- ***Lipopolysaccharide (LPS)-induced systemic inflammation is a well-established model for studying sepsis and its detrimental effects on vital organs, including the liver and kidneys. Both curcumin, a polyphenolic compound derived from Curcuma longa, and piperine, an alkaloid from Piper nigrum, have demonstrated potent anti-inflammatory and antioxidant properties. This review aims to evaluate the protective roles of curcumin and piperine against LPS-induced hepatic and renal damage in Wistar rats. The review highlights the mechanisms by which these compounds exert their effects, including the reduction of oxidative stress, inhibition of pro-inflammatory cytokines, enhancement of antioxidant defenses, and amelioration of histopathological abnormalities. Curcumin modulates various biochemical pathways to reduce inflammation, while piperine enhances curcumin's bioavailability, facilitating its therapeutic efficacy. When used in combination, curcumin and piperine show synergistic effects in reducing LPS-induced organ injury. The co-administration of these compounds not only improves biochemical markers of liver and kidney function but also restores histopathological features, offering a promising therapeutic strategy for managing systemic inflammation. This review synthesizes current findings on the efficacy of curcumin and piperine in mitigating organ damage caused by LPS and discusses their potential as adjuncts to traditional anti-inflammatory therapies.***

Indexed Terms- ***Lipopolysaccharide (LPS), curcumin, piperine, systemic inflammation, hepatic damage, renal damage, antioxidant, inflammation, Wistar rats, synergistic effects.***

I. INTRODUCTION

Systemic inflammation, often modeled by LPS exposure, plays a significant role in multi-organ damage, especially in the liver and kidneys, vital organs involved in detoxification and metabolic regulation. LPS, a bacterial endotoxin, triggers inflammatory pathways through interaction with Toll-like receptor 4 (TLR4), leading to the activation of inflammatory cascades (Aggarwal & Harikumar, 2009). Curcumin and piperine are increasingly studied for their hepatoprotective and nephroprotective properties in the context of LPS-induced injury (Goel et al., 2008).

Systemic inflammation plays a crucial role in the pathogenesis of various diseases, especially those involving multi-organ dysfunction. A commonly used experimental model for studying systemic inflammation is the administration of lipopolysaccharide (LPS), a bacterial endotoxin that triggers an inflammatory response in the body. LPS induces inflammation primarily by activating the Toll-like receptor 4 (TLR4) on immune cells, leading to the release of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) (Medzhitov, 2001). This cascade of cytokine release contributes to tissue damage, particularly in vital organs like the liver and kidneys, which are critical for detoxification and metabolic regulation. The liver and kidneys are highly susceptible to inflammatory damage due to their central role in metabolic homeostasis and immune responses (Zhao et al., 2017).

Curcumin, a polyphenolic compound derived from the rhizomes of Curcuma longa, and piperine, an alkaloid found in Piper nigrum, have garnered significant attention for their potent antioxidant and anti-

inflammatory properties. Both compounds have shown promise in attenuating organ damage in various animal models, including those involving LPS-induced injury. Curcumin exerts its protective effects by modulating inflammatory pathways such as NF-κB and MAPK, as well as enhancing the activity of antioxidant enzymes like superoxide dismutase (SOD) and glutathione (GSH) (Aggarwal & Harikumar, 2009; Goel et al., 2008). Similarly, piperine has been shown to enhance the bioavailability of curcumin and amplify its beneficial effects on oxidative stress and inflammation (Srinivasan, 2007). Together, curcumin and piperine represent a promising therapeutic combination for mitigating LPS-induced hepatic and renal damage

Lipopolysaccharide-Induced Systemic Inflammation and Hepatorenal Injury

Upon LPS exposure, the inflammatory response leads to the excessive release of cytokines such as TNF-α, IL-1β, and IL-6, which further activates oxidative stress and disrupts cellular homeostasis (Mittal et al., 2014). These events contribute to cellular injury, including necrosis, fibrosis, and infiltration of immune cells in the liver and kidney. The resultant biochemical changes include elevated levels of ALT, AST, ALP, creatinine, and urea, markers that indicate compromised organ function.

Curcumin: Pharmacological Profile and Mechanisms of Action

Curcumin, the primary compound in Curcuma longa, is widely recognized for its strong anti-inflammatory, antioxidant, and hepatoprotective effects. It works by increasing the activities of antioxidant enzymes like SOD and GSH while decreasing lipid peroxidation markers such as MDA (Menon & Sudheer, 2007). Additionally, curcumin inhibits key signaling pathways, including NF-κB, reducing the production of pro-inflammatory mediators (Panahi et al., 2016). However, its clinical application is limited due to poor bioavailability, which has led to the development of various strategies to improve its absorption.

Piperine: Pharmacokinetic Enhancer and Anti-Inflammatory Agent

Piperine, found in black pepper, is known to enhance the bioavailability of curcumin by inhibiting its metabolic breakdown in the liver and intestines (Srinivasan, 2007). On its own, piperine possesses anti-inflammatory and antioxidant properties, modulating the production of inflammatory mediators such as COX-2 and iNOS, which contribute to tissue injury (Mujumdar et al., 1990; Srinivasan, 2007). When used in combination with curcumin, piperine significantly boosts the latter's therapeutic effects in LPS-induced hepatic and renal dysfunction.

Synergistic Effects of Curcumin and Piperine

The combined administration of curcumin and piperine has been shown to provide enhanced protection compared to their individual use. Piperine increases curcumin's bioavailability, ensuring more effective modulation of inflammatory responses and oxidative stress. Several studies have demonstrated that this combination improves serum markers (ALT, AST, creatinine, urea) and reduces histopathological damage in both liver and kidney tissues of LPS-treated animals (Patil et al., 2012).

Histopathological and Biochemical Evidence in Wistar Rats

Histological and biochemical assessments have shown that co-treatment with curcumin and piperine results in:

- Normalization of liver and kidney biomarkers (ALT, AST, ALP, creatinine, urea);
- Decreased histological damage such as inflammation, fibrosis, and necrosis in both liver and kidney tissues;
- Increased antioxidant enzyme activity and reduced oxidative damage (Menon & Sudheer, 2007; Srinivasan, 2007; Panahi et al., 2016).

These findings highlight the significant protective effect of curcumin and piperine against LPS-induced organ damage.

Limitations and Future Directions

Despite promising preclinical evidence, there are several challenges in translating these findings to human applications. Variability in animal models,

dosages, and formulations complicates comparisons between studies. Future research should focus on optimizing the delivery systems for curcumin and piperine, exploring nanoparticle-based formulations to improve bioavailability and bioactivity (Panahi et al., 2016). Additionally, long-term safety profiles and potential interactions with other drugs must be thoroughly investigated.

CONCLUSION

The combined use of curcumin and piperine offers a promising therapeutic approach for protecting the liver and kidneys from LPS-induced damage. Their synergistic effects, particularly in improving curcumin's bioavailability, make this combination a potential candidate for managing systemic inflammation and organ dysfunction. Further studies are necessary to validate these effects in clinical settings.

REFERENCES

[1] Aggarwal, B. B., & Harikumar, K. B. (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. International Journal of Biochemistry & Cell Biology, 41(1), 40–59.

[2] Goel, A., Kunnumakkara, A. B., & Aggarwal, B. B. (2008). Curcumin as “Curecumin”: from kitchen to clinic. Biochemical Pharmacology, 75(4), 787–809.

[3] Medzhitov, R. (2001). Toll-like receptors and innate immunity. Nature Reviews Immunology, 1(2), 135–145. https://doi.org/10.1038/35100529

[4] Menon, V. P., & Sudheer, A. R. (2007). Antioxidant and anti-inflammatory properties of curcumin. In Advances in Experimental Medicine and Biology (Vol. 595, pp. 105–125). Springe

[5] Mittal, M., Siddiqui, M. R., Tran, K., Reddy, S. P., & Malik, A. B. (2014). Reactive oxygen species in inflammation and tissue injury. Antioxidants & Redox Signaling, 20(7), 1126–1167.

[6] Mujumdar, A. M., Upadhye, A. S., & Misar, A. V. (1990). Antiinflammatory activity of piperine. Journal of Ethnopharmacology, 29(2), 207–210.

[7] Panahi, Y., Hosseini, M. S., Khalili, N., Naimi, E., Simental-Mendía, L. E., Majeed, M., & Sahebkar, A. (2016). Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. Biomedicine & Pharmacotherapy, 82, 578–582.

[8] Patil, U., Jaydeokar, A., & Bandawane, D. (2012). Immunomodulators: a pharmacological review. International Journal of Pharmacy and Pharmaceutical Sciences, 4(Suppl 1), 30–36.

[9] Srinivasan, K. (2007). Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Critical Reviews in Food Science and Nutrition, 47(8), 735–748.

[10] Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2017). Inflammation and fibrosis in chronic liver diseases: Molecular mechanisms and therapeutic targets. Frontiers in Immunology, 8, 1–15. https://doi.org/10.3389/fimmu.2017.00667